JP2020530499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530499A5 JP2020530499A5 JP2020530715A JP2020530715A JP2020530499A5 JP 2020530499 A5 JP2020530499 A5 JP 2020530499A5 JP 2020530715 A JP2020530715 A JP 2020530715A JP 2020530715 A JP2020530715 A JP 2020530715A JP 2020530499 A5 JP2020530499 A5 JP 2020530499A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- cannabidiol
- subtype
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/099956 WO2019041239A1 (zh) | 2017-08-31 | 2017-08-31 | 大麻二酚在制备抗流感的药物中的用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530499A JP2020530499A (ja) | 2020-10-22 |
| JP2020530499A5 true JP2020530499A5 (enExample) | 2020-12-03 |
| JP6963719B2 JP6963719B2 (ja) | 2021-11-10 |
Family
ID=65524611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530715A Expired - Fee Related JP6963719B2 (ja) | 2017-08-31 | 2017-08-31 | 抗インフルエンザ薬の調製におけるカンナビジオールの用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11452707B2 (enExample) |
| EP (1) | EP3677258B1 (enExample) |
| JP (1) | JP6963719B2 (enExample) |
| AU (1) | AU2017429312B2 (enExample) |
| CA (1) | CA3073576C (enExample) |
| WO (1) | WO2019041239A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113116867B (zh) * | 2019-12-31 | 2022-08-23 | 汉义生物科技（北京）有限公司 | 一种预防和/或治疗流感的组合物 |
| CN111249266B (zh) * | 2020-03-06 | 2022-08-09 | 中国人民解放军海军军医大学 | 帕拉米韦在制备治疗感染性疾病引起炎症风暴的药物中的应用 |
| DK181405B1 (en) * | 2021-05-25 | 2023-10-17 | Cs Medica As | Gel for Intranasal Application, its Provision and Use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110091780A (ko) * | 2008-11-25 | 2011-08-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ６의 길항제 |
| FR2953410B1 (fr) * | 2009-12-09 | 2012-02-24 | Univ Claude Bernard Lyon | Compositions antivirales pharmaceutiques ou veterinaires |
| US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| US9308213B2 (en) * | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
| WO2012104655A2 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
| WO2016092539A1 (en) * | 2014-12-07 | 2016-06-16 | One World Cannabis Ltd | Use of cannabis to treat migraine |
| US20160317468A1 (en) * | 2015-04-28 | 2016-11-03 | Raman Sankar | Uses of cannabidiol for treatment of infantile spasms |
| CA2985969A1 (en) * | 2015-05-13 | 2016-11-17 | One World Cannabis Ltd | Use of cannabis to treat fibromyalgia, methods and compositions thereof |
| MX2018015583A (es) * | 2016-06-15 | 2019-05-16 | Ojai Energetics Pbc | Metodos y composiciones para reducir el estres oxidativo. |
-
2017
- 2017-08-31 EP EP17923262.4A patent/EP3677258B1/en not_active Not-in-force
- 2017-08-31 JP JP2020530715A patent/JP6963719B2/ja not_active Expired - Fee Related
- 2017-08-31 WO PCT/CN2017/099956 patent/WO2019041239A1/zh not_active Ceased
- 2017-08-31 US US16/639,858 patent/US11452707B2/en active Active
- 2017-08-31 CA CA3073576A patent/CA3073576C/en active Active
- 2017-08-31 AU AU2017429312A patent/AU2017429312B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khomich et al. | Redox biology of respiratory viral infections | |
| Govorkova et al. | Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring | |
| Yen et al. | Pandemic influenza as a current threat | |
| Hsieh et al. | Strategies of development of antiviral agents directed against influenza virus replication | |
| Li et al. | Enhancement of influenza virus transmission by gene reassortment | |
| Saha et al. | Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase | |
| Shinya et al. | Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses | |
| Wang et al. | Novel pandemic influenza A (H1N1) virus infection modulates apoptotic pathways that impact its replication in A549 cells | |
| WO2011143262A3 (en) | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses | |
| Govorkova et al. | Therapeutics against influenza | |
| Lu et al. | Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells | |
| Hoffmann et al. | A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment | |
| Gong et al. | Potential targets and their relevant inhibitors in anti-influenza fields | |
| Eyer et al. | Antiviral agents targeting the influenza virus: a review and publication analysis | |
| Zhang et al. | p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo | |
| Ludwig et al. | Influenza, a One Health paradigm—Novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential | |
| Su et al. | Global and quantitative proteomic analysis of dogs infected by avian-like H3N2 canine influenza virus | |
| Ilyushina et al. | In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate | |
| Davis et al. | Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex | |
| Cinatl Jr et al. | The threat of avian influenza A (H5N1). Part III: antiviral therapy | |
| Yang et al. | Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H5N1 | |
| RU2568849C1 (ru) | Средство, представляющее собой амид глицирризиновой кислоты с 5-аминоурацилом, проявляющее противовирусную активность в отношении вируса гриппа a/h1n1 | |
| Zhang et al. | Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening | |
| RU2580305C1 (ru) | ПРОТИВОВИРУСНОЕ СРЕДСТВО НА ОСНОВЕ СУХОГО ЭКСТРАКТА ЛИШАЙНИКА Cetraria islandica | |
| Wu et al. | Transcriptome profiling reveals a peculiarity of host immune responses to PA-X protein of H9N2 influenza A virus |